Christos S. Efessiou, PhD

Management Team: Strategic Pharmaceutical Advisors

Christos S. Efessiou, PhD - Michael A. Kaliner, MD - William W. Storms, MD

Christos S. Efessiou, PhD

Telephone: 202.965.2288
Email: cefessiou@SRxA.com
Curriculum Vitae (pdf file)

Christos Efessiou is the Chief Executive Officer of Strategic Pharmaceutical Advisors (SRxA) and Affiliated Companies, a life sciences consulting, marketing and professional education company, and the Chief Executive Officer of Strategic Pharmaceuticals Company, doing business as Strategic BioSciences.  His career spans over 20 years of experience in pharmaceutical marketing, continuing medical education, distance learning, pharmaceutical product management, market research, market planning, pharmaceutical sales and management, and clinical practice in respiratory care and extracorporeal circulation.

Prior to co-founding SRxA he founded Strategic Implications International (SII), a healthcare education company, which became among the first commercial entities to be accredited by the ACCME as a Continuing Medical Education provider.  SII developed and operated the first all-credited content website (cme-ce.com) in 1996, and in 1998 the company became the first content provider to offer credited CME courses through the AOL Digital Cities network.

He co-founded Cogent Interactive Communications in 1994, which was later merged with SII. In 1998 SII was acquired and continues to trade to this day under its original name as a division of Cardinal Health.  The company was involved in numerous new product launches, primarily in the Respiratory, CNS, and Oncology arenas. Major new product introductions included Serevent, Fluovent, Fluonase, Imitrex, Zantac, and others.

As a product manager at Boehringer Ingelheim Pharmaceuticals, he was responsible for the launch of Ipratropium bromide (Atrovent) in the United States, the development of the strategic plan for the launch of Clonidine Transdermal Therapeutic System (Catapres-TTS) globally, the introduction of numerous line extensions of Metaproterenol (Alupent), and the management of multiple CNS products.  While at Boehringer Mannheim Pharmaceuticals, he was responsible for the company's first NDA filing, and numerous product licensing and acquisition deals.

Prior to the commencement of his pharmaceutical career, he directed the Continuing Education Department at Newton-Wellesley Hospital, a Tufts Medical School Affiliate, and developed the hospital's first Out-Patient Respiratory Care Clinic under the medical direction of Dr. Gustav Laurenzi. His experience includes clinical practice in Critical Respiratory Care and Extracorporeal Circulation at Brigham and Women's Hospital, and Cardiac Anesthesia Research at the Massachusetts General Hospital in Boston. He is Board Certified and Registered by the American Board for Respiratory Care (Reg. No: 20218).

He served as project funding evaluator to the European Commission (EUROPA) Directorate General Information Society (former DG XIII) in 1995.  He has coauthored several clinical publications, and he lectures frequently on various topics nationally and internationally.  He is a Lifetime VIP Member of the Presidential Who’s Who among Business and Professional Achievers (2008), the Cambridge Who’s Who (2007), the Marquis Who’s Who in Medicine & Healthcare 2004-2005, the Who’s Who among top Executives (1997), The Sterling Who’s Who Executive Edition, and The Who’s Who Worldwide Registry of Business Leaders.  He is a Federal Aviation Administration (FAA) licensed Private Pilot with an Instrument Rating.

A Magna Cum Laude graduate of Northeastern University, he was inducted in the Sigma Epsilon Rho Honor Society in 1985.  He was elected a Director of the University’s National Council (2001-2003), served as an advisor to the interim Dean of The College of Health Sciences (1998-2000), and was the Speaker at the Graduation Ceremonies of the College of Health Sciences in 2001.